#162 - Sarah Hallberg, D.O., M.S.: Challenging the status quo of treating metabolic disease, and a personal journey through a grim cancer diagnosis

May 17, 2021 Episode Page ↗
Overview

Dr. Sarah Hallberg discusses carbohydrate restriction's efficacy for type 2 diabetes and obesity, challenging dietary fat beliefs, and highlighting palmitoleic acid as an early metabolic disease predictor. She also shares her personal journey with stage four lung cancer, emphasizing living fully, honest family communication, and the critical need for self-advocacy and health equity in cancer care.

At a Glance
16 Insights
2h 21m Duration
15 Topics
8 Concepts

Deep Dive Analysis

Introduction to Sarah Hallberg and Type 2 Diabetes

Dietary Fat, Carbohydrates, and Plasma Fatty Acid Distribution

Sarah's Journey to Carbohydrate Restriction for Diabetes

Institutional Acceptance and Early Clinical Trials

Prevalence and Early Indicators of Prediabetes and Metabolic Syndrome

Challenging the 'You Are What You Eat' Dogma in Fat Metabolism

Palmitoleic Acid (POA) as a Key Biomarker for Metabolic Health

Individualized Carbohydrate Tolerance and Metabolic Management

Sarah's Lung Cancer Diagnosis and Emergency Brain Surgery

Coping with Grief and Denial After a Terminal Diagnosis

Understanding Non-Smoking Lung Cancer and its Demographics

Pursuing Aggressive Treatment and Battling Cancer Mutations

Life-Threatening Chemotherapy Complications and Recovery

Challenges and Delays in Cancer Recurrence Treatment

Reflections on Living with Chronic Cancer and Advocacy

De Novo Lipogenesis

This is the process where the liver synthesizes fat from non-fat precursors, primarily carbohydrates. It contributes significantly to elevated triglycerides and VLDL, and its acceleration is correlated with insulin resistance and adiposity.

Palmitoleic Acid (POA) / C16-1

A monounsaturated fatty acid with 16 carbons and one double bond, produced from palmitic acid (C16-0) by the SCD1 enzyme. Elevated POA levels serve as an important early biomarker for insulin resistance and carbohydrate intolerance, even before blood sugar rises.

Sterol-CoA Desaturase (SCD1)

Also known as Delta-9 desaturase, this enzyme converts saturated fatty acids into monounsaturated fatty acids, such as palmitic acid into palmitoleic acid. Increased SCD1 activity is an independent marker of triglyceridemia and abdominal adiposity, indicating increased fat synthesis and export from the liver.

Metabolic Syndrome

A cluster of five conditions (elevated blood pressure, high fasting glucose, high triglycerides, low HDL cholesterol, and truncal obesity) that collectively increase the risk of heart disease, stroke, and type 2 diabetes. Studies indicate that 88% of adult Americans do not meet the criteria for optimal metabolic health.

Carbohydrate Tolerance

Refers to an individual's capacity to consume carbohydrates without triggering adverse metabolic responses, such as increased de novo lipogenesis and elevated palmitoleic acid. This tolerance varies significantly among individuals and can change over time, influencing personalized dietary recommendations.

EGFR-Driven Lung Cancer

A specific type of non-small cell lung cancer, often found in non-smokers, characterized by mutations in the epidermal growth factor receptor (EGFR) gene. These cancers can be targeted by specific tyrosine kinase inhibitor (TKI) therapies, but often develop resistance over time.

Tyrosine Kinase Inhibitors (TKIs)

A class of targeted cancer drugs that block the activity of specific tyrosine kinase enzymes, which are involved in cell growth and division. TKIs are highly effective for cancers with certain mutations, like EGFR-driven lung cancer, but typically lead to temporary remission as cancer cells eventually develop resistance.

Atypical Hemolytic Uremic Syndrome (aHUS)

A rare and severe medical complication, in Sarah's case triggered by chemotherapy (gemcitabine), characterized by multi-organ failure affecting kidneys, liver, and respiratory system. It has a high mortality rate and often leads to permanent dialysis, with treatment involving specialized medications like plasmapheresis.

?
Why is the relationship between dietary fat/carbohydrate and plasma fatty acids important?

It challenges the 'you are what you eat' dogma, showing that dietary saturated fat intake does not directly correlate with serum saturated fat levels, especially in the context of carbohydrate restriction, and highlights internal fat synthesis as a key factor.

?
What is the prevalence of metabolic health issues in America?

Over 50% of adult Americans have diabetes or pre-diabetes, and a staggering 88% are not in optimal metabolic health, based on NHANES data and metabolic syndrome criteria.

?
What is palmitoleic acid (C16-1) and why is it a significant biomarker?

Palmitoleic acid is a monounsaturated fatty acid produced by the SCD1 enzyme, and its elevated levels are an early predictor of insulin resistance, triglyceridemia, and future diabetes, even before blood sugar levels rise.

?
Can type 2 diabetes be reversed, and can patients reintroduce carbohydrates?

Yes, type 2 diabetes can often be reversed with very low carbohydrate diets, and many patients can gradually reintroduce some carbohydrates if they have sufficient functioning beta cells, though individual carbohydrate tolerance varies.

?
What is the typical prognosis for stage four lung cancer, especially in non-smokers?

The median survival for stage four lung cancer can be 12 months or less, and non-smoking lung cancer, often adenocarcinoma with specific mutations like EGFR, is growing at alarming rates, frequently affecting healthy, thin young women.

?
How do targeted therapies like TKIs work for EGFR-driven lung cancer?

Tyrosine kinase inhibitors (TKIs) can effectively shrink or eliminate tumors in EGFR-driven lung cancer by blocking specific enzymes, but they are not a cure, as the cancer typically develops resistance and recurs over time.

?
What challenges do cancer patients face, even those with significant resources?

Even privileged patients face significant delays in accessing appropriate care for cancer recurrence, high out-of-pocket costs, and a healthcare system that often 'gives up' on patients once their cancer returns, highlighting issues of health equity.

1. Optimize Sleep, Exercise, Nutrition

Prioritize optimizing the “sleep, exercise, nutrition trifecta” and managing cortisol, as getting these right can significantly reduce the risk of heart disease, cancer, and Alzheimer’s disease.

2. Consider Therapeutic Carb Restriction

For individuals with type 2 diabetes or metabolic syndrome, a therapeutic carbohydrate-restricted diet (e.g., less than 50 grams/day) can significantly decrease triglycerides, improve glycemic control, and in many cases, reverse type 2 diabetes.

3. Monitor Palmitoleic Acid (POA) Levels

Consider monitoring palmitoleic acid (POA) levels as a biomarker, as elevated POA can indicate that an individual has consumed carbohydrates above their personal tolerance, even with normal blood sugar, serving as an early warning sign of metabolic trouble.

4. Be Hypervigilant About Blood Sugar

Physicians and patients should not ignore any elevation in blood sugar, even in the pre-diabetic range, as it indicates a long-standing underlying problem that requires immediate attention.

5. Understand Individual Carb Tolerance

Determine your individual carbohydrate tolerance, as this is key to personalized nutrition and health management, rather than relying solely on population-level data.

6. Utilize Continuous Glucose Monitoring

Consider using continuous glucose monitoring (CGM) even if not diabetic, to maintain a high standard of average glucose and manage glucose excursions, as an early detection tool for metabolic health.

7. Reduce Insulin Dependency

Understand that insulin is not benign; aim to reduce insulin requirements as much as possible, as a lower daily dose to achieve normal glycemia represents a significant improvement in health outcomes.

8. Reframe Obesity as a Disease

Understand that obesity is a disease process that often begins before significant weight gain and is not the patient’s fault, requiring providers to approach and treat these patients without bias.

9. Address Provider Bias in Obesity Care

Healthcare providers should self-reflect on and address any biases they hold against patients struggling with weight, recognizing that obesity is a complex disease process and not the patient’s fault.

10. Transform Anger into Action

When experiencing anger or frustration from life’s challenges, channel that emotion into productive action and advocacy rather than allowing it to consume you.

11. Choose to Live Fully

When faced with profound adversity or a terminal diagnosis, choose to actively live and make the most of your time, as this approach can positively impact your family and your own well-being.

12. Be Honest with Children

When dealing with a serious illness, commit to always telling children the truth about the situation, as constant uncertainty can be more detrimental than knowing the facts.

13. Become an Expert Patient Advocate

Develop strong self-advocacy skills in healthcare, especially when facing complex diagnoses like cancer, as the system may not always provide optimal support without persistent pushing.

14. Educate Stakeholders on New Approaches

When introducing an unconventional treatment or approach, proactively educate all relevant departments and stakeholders with evidence-based presentations to address potential resistance and gain buy-in.

15. Offer Carb Restriction Option

Physicians should provide all patients with metabolic disease the option of trying a carbohydrate-restricted diet, as it is based on evidence and can lead to significant improvements.

16. Acknowledge Personal Reality

Be realistic and honest about your emotional state and challenges, especially when facing severe illness, rather than pretending everything is “great” or adopting a “superwoman” facade.

88% of adult Americans are not in optimal metabolic health.

Sarah Hallberg

By the time you get to prediabetes, there's some really serious things going on here. Their vision is being impacted. Their nerves are being impacted. You know, these are things we can't just say, oh, they haven't, they haven't gotten bad enough to bother with because they're not at the criteria for type 2 diabetes yet.

Sarah Hallberg

Obesity is not the cause of metabolic illness, but the result of it.

Peter Attia

The mandatory discussion that needs to occur is, I'm going to give this medication, this insulin that you're going to inject to you. And I'm going to do that because your blood sugars are so high that they could acutely kill you, put you into the hospital, put you at risk of all these complications. But I just want you to know, you're more likely to die on insulin. That's what we need to tell people.

Sarah Hallberg

Your kids are going to be better if you choose to live.

Sarah Hallberg

I don't care about anything outside of the walls of this house. And I would take a selfish approach in some ways, I think. And you've done this very selfless thing, which is continuing to sort of prioritize everything else as well. How do you do that?

Peter Attia

Bad things happen to good people. Like I said, there's been a pivot in every part of my career based on anger. And I certainly am angry about this. But what do you do with it? That's what's going to be the important question in life.

Sarah Hallberg

I just want to be a normal person.

Sarah Hallberg

Sarah Hallberg's Aggressive Cancer Treatment Strategy (post-TKI resistance)

Sarah Hallberg
  1. Continue the tyrosine kinase inhibitor (TKI) (e.g., Osimertinib) without interruption.
  2. Undergo regular cycles of chemotherapy (e.g., Cisplatin) to reduce tumor burden.
  3. Immediately after chemo, initiate anti-estrogen therapy, including medications like Lupron, Fulvestrant, and Pablacyclib, to target specific secondary mutations.
  4. Following anti-estrogen therapy, cycle through different single-agent, very low-dose chemotherapies (e.g., Gemcitabine, Taxols) to prevent new mutations and resistance.
  5. Proactively battle potential mutations by constantly changing treatments, rather than waiting for cancer to return or develop resistance.
Over 50%
Percentage of adult Americans with diabetes or pre-diabetes Based on recent studies
88%
Percentage of adult Americans not in optimal metabolic health Based on NHANES data and metabolic syndrome criteria
5.7% to 6.4%
Hemoglobin A1c range for pre-diabetes Standard definition
Over 110 mg/dL
Fasting glucose level for pre-diabetes Worrisome range
Less than 100 mg/dL
Normal fasting glucose Standard definition
Less than 150 mg/dL
Normal triglycerides Standard definition; Peter's practice advocates for less than 100 mg/dL
Greater than 40 mg/dL
Normal HDL cholesterol for men Standard definition
Greater than 50 mg/dL
Normal HDL cholesterol for women Standard definition
40 inches
Waist circumference for truncal obesity (men) Standard definition
36 inches
Waist circumference for truncal obesity (women) Standard definition
12% to 14%
Percentage of lung cancer patients who are non-smokers Often get adenocarcinoma type
46
Sarah Hallberg's age at lung cancer diagnosis Diagnosed in June 2017
7, 12, and 14
Sarah Hallberg's children's ages at diagnosis At the time of her diagnosis
12 months or less
Median survival for stage four lung cancer Can be 8 months or less depending on type
8 to 30 months
Typical duration of TKI effectiveness for EGFR cancer Average 8 months, advanced ones up to 24-30 months
6
Sarah Hallberg's hemoglobin level during multi-organ failure Normal is 13-14
23
Sarah Hallberg's platelet count during multi-organ failure Normal is much higher, indicating severe clotting impairment
4 months
Delay for Sarah Hallberg to get on a clinical trial for cancer recurrence From mid-September diagnosis to December 30th start